Drug
Ursodeoxycholic acid (UDCA) 500 mg
Ursodeoxycholic acid (UDCA) 500 mg is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
67%
Ph not_applicable
1
33%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (66.7%)
N/A1 (33.3%)
Trials by Status
completed267%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingnot_applicable
Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance
NCT06684106
completedphase_2
Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis
NCT05973370
completedphase_2
Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis
NCT04834557
Clinical Trials (3)
Showing 3 of 3 trials
NCT06684106Not Applicable
Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance
NCT05973370Phase 2
Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis
NCT04834557Phase 2
Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3